<%@ Page Title="" Language="C#" MasterPageFile="~/masterpages/module.master" AutoEventWireup="true" CodeFile="reading.aspx.cs" Inherits="secure_modules_module4_reading" %>

<asp:Content ID="Content1" ContentPlaceHolderID="contentBreadcrumb" Runat="Server">
     Leczenie \ Zalecana literature
</asp:Content>
<asp:Content ID="Content2" ContentPlaceHolderID="contentSideBar" Runat="Server">
</asp:Content>
<asp:Content ID="Content3" ContentPlaceHolderID="contentMain" Runat="Server">
    <div class="module4page">
        <h1>
            Zalecana literature</h1>
        <h2>
            Przestrzeganie zaleceń
        </h2>
        <br />
         <div class="icon_reading">
        <ul>
            <li><span>
                    Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. 
                <i>Medscape J Med</i>. 2008;10:225. 
            </span></li>
            <li><span>
                    Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. 
                <i>Patient Prefer Adherence</i>. 2010;4:1-9. 
            </span></li>
            <li><span>
                    Twork S, Nippert I, Scherer P, et al. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. 
                <i>Curr Med Res Opin</i>. 2007;23:1209-1215.
            </span></li>
        </ul>
        </div>
        <h2>
            Leczenie objawów
        </h2>
        <br />
         <div class="icon_reading">
        <ul>
            <li><span>
                    Ben-Zacharia AB. Therapeutics for multiple sclerosis symptoms. 
                <i>Mt Sinai J Med</i>. 2011;78(2):176-191.
            </span></li>
            <li><span>
                    Berger JR. Functional improvement and symptom management in multiple sclerosis: Clinical efficacy of current therapies.  
                <i>Am J Manag</i> Care 2011; 17 Suppl 5: S146−53.
            </span></li>
            <li><span>
                    Samkoff LM, Goodman AD. Symptomatic management in multiple sclerosis. 
                <i>Neurol Clin</i>. 2011;29(2):449-463.
            </span></li>
            <li><span>
                    Hasselkorn JK, Balsdon RC, Fry WD, <i>et al</i>. Overview of spasticity management in multiple sclerosis: evidence-based management strategies for spasticity treatment in multiple sclerosis. 
                <i>J Spinal Cord Med</i>. 2005;28:173-197.
            </span></li>
            <li><span>
                    Amato MP, Portaccio E. Management options in multiple sclerosis-associated fatigue. 
                <i>Expert Opin Pharmacother</i> 2012; 13(2): 207−16.
            </span></li>
            <li><span>
                    Lombardi G, Macchiarella A, Del Popolo G. Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis. 
                <i>J Sex Med</i> 2010; 7(6): 2192−200.
            </span></li>
        </ul>
        </div>
        <h2>
            Terapie modyfikujące przebieg choroby
        </h2>
        <br />
         <div class="icon_reading">
        <ul>
            <li><span>
                    Harris C, Halper J. <i>Best Practices in Nursing Care: Disease Management, Pharmacological Treatment, Nursing Research</i>, 3rd Edition. Bioscience Communications. 2008.
            </span></li>
            <li><span>
                    Brandes DW, Callender T, Lathi E, et al. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. 
                <i>Curr Med Res Opin</i>. 2009;25:77-92.
            </span></li>
            <li><span>
                    Kappos L, Polman CH, Freedman MS, <i>et al</i>. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67(7): 1242−9.
            </span></li>
            <li><span>
                    Comi G, Martinelli V, Rodegher M, <i>et al</i>. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374(9700): 1503−11.
            </span></li>
            <li><span>
                    O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. 
                <i>Lancet Neurol</i> 2009; 8(10): 889−97.
            </span></li>
            <li><span>
                    Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. 
                <i>Lancet</i> 2007; 370(9585): 389−97.
            </span></li>
            <li><span>
                    Kappos L, Radue EW, O'Connor P, <i>et al</i>. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. 
                <i>N Engl J Med</i> 2010; 362(5): 387–401.
            </span></li>
            <li><span>
                    Cohen JA,  Barkhof F, Comi G, <i>et al</i>. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
                <i>N Engl J Med </i>2010; 362(5): 402–15.
            </span></li>
            <li><span>
                    Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. 
                <i>Lancet Neurol </i>2011; 10(6): 520–9.
            </span></li>
            <li><span>
                    Polman CH, O'Connor PW, Havrdova E, et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. 
                <i>N Engl J Med </i>2006; 354(9): 899−910.
            </span></li>
            <li><span>
                    Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. 
                <i>N Engl J Med</i> 2006; 354(9): 911-923.
            </span></li>
            <li><span>
                    loomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.  
                <i>N Engl J Med </i>2012; 366(20): 1870−80.
            </span></li>
            <li><span>
                    Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double-blind, randomised, multicentre trial. 
                <i>Lancet</i> 2002; 360(9350): 2018–25.
            </span></li>
        </ul>
        </div>
    </div>
</asp:Content>

